产品说明书

Sulfapyridine

Print
Chemical Structure| 144-83-2 同义名 : NSC 41791;NSC 4753;Pyriamid;Plurazol;A 499;Sulphapyridine
CAS号 : 144-83-2
货号 : A313387
分子式 : C11H11N3O2S
纯度 : 98+%
分子量 : 249.289
MDL号 : MFCD00038036
存储条件：

粉末 Keep in dark place,Sealed in dry,Room Temperature

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 60 mg/mL(240.68 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
描述 Sulfasalazine was the first aminosalicylate to be used for induction and maintenance therapy of ulcerative colitis (UC)[3]. Sulfasalazine is a potent inhibitor of superoxide production and granule enzyme release by stimulated neutrophils, and modulation of these responses may contribute to its anti-inflammatory properties. The inhibitory effects of sulfasalazine on superoxide production, degranulation and neutrophil-mediated collagen degradation were closely mimicked by olsalazine[4]. Sulfasalazine and sulfapyridine but not 5-aminosalicylate inhibit spontaneous cytotoxicity mediated by human natural killer (NK) cells[5].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01596777 Intestinal Obstruction Phase 1 Completed - Germany ... 展开 >> Department of Clinical Pharmacology, Ernst-Moritz-Arndt-University Greifswald Greifswald, Mecklenburg-Vorpommern, Germany 收起 <<
NCT00637780 Arthritis, Juvenile Rheumatoid Phase 4 Terminated(Study terminated on... 展开 >> 13 April 2016 for business reasons. No safety and/or efficacy concerns contributed to the termination of the study) 收起 << - United States, Ohio ... 展开 >> University Hospitals Case Medical Center Cleveland, Ohio, United States, 44106 Mexico Private Office Guadalajara, Jalisco, Mexico, 44650 收起 <<
NCT01596764 Intestinal Obstruction Phase 1 Completed - Germany ... 展开 >> Department of Clinical Pharmacology, Ernst-Moritz-Arndt-University Greifswald Greifswald, Mecklenburg-Vorpommern, Germany 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

4.01mL

0.80mL

0.40mL

20.06mL

4.01mL

2.01mL

40.11mL

8.02mL

4.01mL
参考文献

[1]Marzano IM, Franco MS, et al. Crystal structure, antibacterial and cytotoxic activities of a new complex of bismuth(III) with sulfapyridine. Molecules. 2013 Jan 24;18(2):1464-76.

[2]Hanauer SB. Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis. Aliment Pharmacol Ther. 2006 Oct;24 Suppl 3:37-40.

[3]Hanauer SB. Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis. Aliment Pharmacol Ther. 2006;24 Suppl 3:37–40.

[4]Neal TM, Winterbourn CC, Vissers MC. Inhibition of neutrophil degranulation and superoxide production by sulfasalazine. Comparison with 5-aminosalicylic acid, sulfapyridine and olsalazine. Biochem Pharmacol. 1987;36(17):2765–2768.

[5]Shanahan F, Niederlehner A, MacDermott RP, Stenson WF, Kane MG, Targan S. Inhibition of cytotoxicity by sulfasalazine. II. Sulfasalazine and sulfapyridine inhibit different stages of the NK and NKCF lytic processes. Immunopharmacology. 1986;11(2):111–118.